One Person Gets a New Weight Loss Drug
One Person Gets a New Weight Loss Drug
一人獲准使用新型減肥藥
Introduction
The FDA and a company called Eli Lilly let one person use a new drug. This drug is for people who are very overweight.
FDA 和一家名為 Eli Lilly 的公司允許一名患者使用一種新藥。這款藥物是針對體重嚴重超標的人群。
Main Body
The drug is called retatrutide. It helps people lose a lot of weight. Doctors are still testing it. Usually, the FDA only gives new drugs to very sick people who have no other help.
這種藥物被稱為 retatrutide，能幫助人們減掉大量體重。醫生目前仍在進行測試。通常情況下，FDA 僅會將新藥提供給沒有其他治療選擇的重病患者。
A doctor asked for the drug for a 79-year-old patient. This person is very overweight and has heart and sleep problems. The person is too old for surgery.
一位醫生為一名 79 歲的患者申請了該藥物。該患者體重嚴重超標，且患有心臟與睡眠問題。由於年齡過大，該患者不適合接受手術。
Some experts say this is strange. They say the FDA does not usually give a new drug to only one person. People ask if the patient is Donald Trump. The government does not say yes or no.
一些專家表示這很奇怪。他們認為 FDA 通常不會僅允許一個人使用新藥。人們質疑該患者是否為川普。政府對此既未肯定也未否定。
Conclusion
One person is using a new drug. This is not normal. We do not know who the person is.
有人正在使用新藥，這並不尋常。我們不知道該患者是誰。
Vocabulary Learning
The 'People' Pattern
In this text, we see how to describe people using simple groups and specific details. To reach A2, you need to connect a person to their problem.
1. General Groups
- "People who are very overweight"
- "Very sick people"
2. Specific Details
- "A 79-year-old patient"
- "One person"
How it works →
When we talk about a group, we use People who... + description.
- Example: People who live in New York (Group)
- Example: People who like coffee (Group)
The A2 Shortcut: Instead of saying "He is old and sick," the text says "A 79-year-old patient." This turns the age into a description (an adjective) before the person (the noun).
- Patient (The person)
- 79-year-old (The description)
Quick Vocabulary from the text:
- Patient: A person seeing a doctor.
- Expert: A person who knows a lot about a subject.
- Government: The people who run a country.
Vocabulary Learning
FDA Grants Special Access to Experimental Obesity Drug for One Person
FDA 特別允許一人使用實驗性肥胖藥物
Introduction
The Food and Drug Administration (FDA) and Eli Lilly have allowed one person to use retatrutide, an experimental weight-loss drug, through a special process known as 'compassionate use'.
美國食品藥物管理局 (FDA) 與禮來公司 (Eli Lilly) 允許一名人士透過一項稱為「同情使用」(compassionate use) 的特殊程序，使用一種名為 retatrutide 的實驗性減肥藥。
Main Body
Retatrutide is a new type of medication that targets three different receptors to help reduce weight. In a Phase 3 clinical trial, non-diabetic patients with obesity lost 28 percent of their body weight over 80 weeks, which is a result similar to what is achieved through weight-loss surgery. Usually, the FDA's 'compassionate use' program is only for patients with life-threatening illnesses who have no other treatment options and cannot join a clinical trial.
Retatrutide 是一種新型藥物，透過針對三種不同的受體來幫助減重。在一次第三期臨床試驗中，患有肥胖症但非糖尿病的患者在 80 週內減輕了 28% 的體重，結果與減重手術所達到的效果相似。通常，FDA 的「同情使用」計畫僅適用於患有危及生命疾病、沒有其他治療選擇且無法參加臨床試驗的患者。
In April, a senior doctor from the National Institutes of Health (NIH) requested the drug for a 79-year-old patient. This patient suffered from severe obesity, high blood pressure in the lungs, and sleep apnea. Because of the patient's age and other health problems, surgery was not an option, and a previous weight-loss drug had only worked moderately well.
四月，美國國家衛生研究院 (NIH) 的一名資深醫生為一名 79 歲的患者申請了該藥物。該患者患有嚴重肥胖、肺高壓症和睡眠呼吸暫停症。由於患者年齡較大且有其他健康問題，手術並非可行方案，且先前使用的減重藥物效果僅一般。
However, some experts have raised concerns about how this was handled. Richard Klein, who helped create the expanded access program, emphasized that the public notice was missing standard details, making it very hard to find. Furthermore, medical experts asserted that giving this access to just one person for common health conditions is very unusual. When asked if the patient is President Donald Trump, the White House and the Department of Health and Human Services (HHS) did not give a clear answer, stating only that the FDA reviews each case individually.
然而，部分專家對此處理方式提出擔憂。協助建立擴大獲取計畫的 Richard Klein 強調，公開通知中缺少標準細節，導致極難搜尋。此外，醫學專家主張，針對常見健康狀況而僅允許一人使用，是非常罕見的。當被問及患者是否為總統川普時，白宮與衛生及公共服務部 (HHS) 並未給出明確答覆，僅表示 FDA 會對每個個案進行個別審查。
Conclusion
This case is a very rare example of a single person receiving an experimental drug, and the identity of the patient has not been officially confirmed.
此案例是一個非常罕見的例子，即僅有一名人士獲得使用實驗性藥物的許可，且患者的身份尚未正式確認。
Vocabulary Learning
The 'Precision Shift': From Simple to Sophisticated
To move from A2 to B2, you must stop using generic words like good, bad, or big and start using Precise Modifiers. In this text, we see a perfect example of how to describe 'degree' and 'quality' without sounding like a beginner.
⚡ The Upgrade Path
Look at how the text describes the patient's situation. Instead of saying "The patient was very sick," it uses specific combinations:
- Severe obesity (Not just 'very fat', but a clinical level of seriousness).
- Moderately well (Not just 'okay', but a measured, medium level of success).
- Very rare (Not just 'not common', but emphasizing an extreme exception).
🛠️ B2 Power Move: The 'Adverb + Adjective' Combo
At the A2 level, you likely say: "The drug is new." At the B2 level, you describe the nature of that newness:
*"...an experimental weight-loss drug..."
Why this matters: "Experimental" tells us the drug is new, but it also tells us it is being tested and might be risky. That is the difference between basic communication and B2 fluency.
🔍 Spotting the 'Professional Tone'
Notice the word "asserted."
- A2: "Experts said that..."
- B2: "Medical experts asserted that..."
Using asserted instead of said transforms the sentence from a simple conversation into a formal argument. It suggests confidence and authority.
Quick Tip for your transition: Next time you want to say something is "very [adjective]," challenge yourself to find a specific B2 word (like severe, significant, or exceptional) to replace it.
Vocabulary Learning
Authorization of Expanded Access for Experimental Obesity Pharmacotherapy to a Single Individual
授權單一人士擴大使用實驗性肥胖藥物治療
Introduction
The Food and Drug Administration (FDA) and Eli Lilly have permitted one individual to receive retatrutide, an experimental obesity treatment, via the compassionate use pathway.
美國食品藥物管理局 (FDA) 與禮來公司 (Eli Lilly) 已允許一名人士透過「同情使用」途徑，接受一種名為 retatrutide 的實驗性肥胖治療藥物。
Main Body
The pharmacological agent in question, retatrutide, is a next-generation candidate targeting GIP, glucagon, and GLP-1 receptors. Clinical data from a Phase 3 trial indicated a 28 percent reduction in body mass over 80 weeks in non-diabetic obese patients, a result quantitatively comparable to bariatric surgical interventions. While the drug remains in late-stage trials for obesity, sleep apnea, and diabetes, the FDA's 'compassionate use' or expanded access program is typically reserved for patients with life-threatening conditions who lack alternative therapeutic options and are ineligible for clinical trials.
該藥物 retatrutide 是一種針對 GIP、glucagon 及 GLP-1 受體的次世代候選藥物。第三期臨床試驗數據顯示，非糖尿病肥胖患者在 80 週內體重減少了 28%，此結果在量化上與減重手術相當。雖然該藥物仍處於肥胖、睡眠呼吸暫停及糖尿病的後期試驗階段，但 FDA 的「同情使用」或擴大使用計劃通常僅保留給缺乏替代治療方案且不符合臨床試驗資格的危及生命患者。
Administrative records indicate that a request was submitted in April by Ranganath Muniyappa, a senior clinician at the National Institutes of Health (NIH), on behalf of a 79-year-old patient. The clinical profile cited included refractory obesity, pulmonary hypertension, and obstructive sleep apnea. The patient had previously undergone a one-year regimen of tirzepatide with only moderate efficacy and was deemed unsuitable for bariatric surgery due to age and comorbid conditions.
行政記錄顯示，美國國家衛生研究院 (NIH) 的資深臨床醫生 Ranganath Muniyappa 於 4 月代表一名 79 歲患者提交了申請。引用的臨床概況包括難治性肥胖、肺高壓症及阻塞性睡眠呼吸暫停症。該患者先前接受了為期一年的 tirzepatide 治療，但療效僅中等，且因年齡及併發症而被認為不適合進行減重手術。
Procedural anomalies have been noted regarding the public notification of this access. Richard Klein, a former architect of the expanded access program, asserted that the notice lacked standard qualifying criteria, rendering it virtually undetectable except to those specifically searching for the drug's nomenclature. Furthermore, medical experts have characterized the granting of such access to a single individual for common conditions, rather than a defined patient cohort, as highly irregular. Inquiries directed to the White House and the Department of Health and Human Services (HHS) regarding whether the patient is President Donald Trump were not definitively answered; the White House deferred to HHS, which provided a generalized statement on the FDA's case-by-case review process.
關於此次授權的公開通知，其程序異常之處已被指出。擴大使用計劃的前策劃者 Richard Klein 主張，該通知缺乏標準的資格基準，使得除了專門搜尋該藥物名稱的人之外，幾乎無法被察覺。此外，醫學專家將針對普通病症而非定義的患者群體，向單一人士授予此類權限的行為描述為高度異常。針對該患者是否為總統川普的詢問被轉至白宮及衛生與公共服務部 (HHS)，但未能獲得明確答覆；白宮將此事推給 HHS，而 HHS 僅就 FDA 的個案審查流程提供了一份概括性聲明。
Conclusion
The current situation involves a singular, highly irregular instance of expanded access to an experimental drug, the identity of the recipient of which remains officially unconfirmed.
目前的情況涉及一個極其異常的單一實驗性藥物擴大使用個案，而接收者的身份仍未正式確認。
Vocabulary Learning
The Architecture of Euphemistic Precision
To move from B2 to C2, a student must stop merely 'describing' and start 'framing'. This text is a masterclass in Administrative Euphemism—the art of using clinical, detached language to describe highly controversial or anomalous events without assigning explicit blame or emotion.
⚡ The 'C2 Pivot': Nominalization as a Shield
Notice how the text avoids direct action verbs in favor of heavy nominalization. This removes the 'actor' and focuses on the 'process,' creating a veneer of objectivity common in high-level diplomacy and legal writing.
- B2 Approach: "The FDA did something strange when they notified the public."
- C2 Execution: "Procedural anomalies have been noted regarding the public notification of this access."
Analysis: By transforming the action (notifying) into a noun (notification) and the mistake (strange thing) into a formal noun (procedural anomalies), the writer achieves a level of professional distance that is essential for C2-level academic and professional registers.
🔍 Lexical Nuance: The 'Qualified' Adjective
C2 mastery is found in the selection of modifiers that subtly signal judgment while maintaining a neutral tone. Examine these pairings:
- "Quantitatively comparable": Rather than saying "as good as," this phrase specifies that the numbers match, leaving room for the possibility that the quality or risk does not.
- "Highly irregular": In a C2 context, this is a 'coded' phrase. It is a polite way of saying "this is potentially illegal or unethical" without risking a libel lawsuit.
- "Refractory obesity": A medical term used to indicate that a condition is resistant to treatment. Using specific terminology (refractory vs. stubborn) shifts the text from a general report to a professional dossier.
🛠 Sophisticated Syntactic Structures
Observe the use of the Passive Voice + Modal Adverb to create a sense of officialdom:
"...rendering it virtually undetectable..."
The use of "virtually" here is a precision tool. It acknowledges that while the notice exists (technically detectable), for all practical purposes, it is hidden. This 'hedging' is a hallmark of C2 proficiency—the ability to avoid absolute statements to maintain intellectual and legal rigor.